You searched for: add on therapy (Engelska - Maltesiska)

add on therapy
terapija addizzjonali

add-on therapy
terapija miżjuda

on-therapy genotypes
51 (100%) 2 genotipi fuq terapija

alogliptin as add-on therapy to metformin
alogliptin bħala terapija aġġuntiva ma’ metformin

add-on therapy with insulind (18 weeks)
terapija miżjuda mal-insulinad (18-il ġimgħa)

alogliptin as add-on therapy to metformin with insulin
alogliptin bħala terapija miżjuda għal metformin mal-insulina

alogliptin as add-on therapy to a thiazolidinedione with metformin
alogliptin bħala terapija miżjuda ma’ thiazolidinedione b’metformin

the efficacy as an add-on therapy has not been demonstrated.
l-effikaċja bħala terapija addizzjonali ma ntwerietx.

add-on therapy for infants and children less than 4 years
terapija miżjuda fi trabi u tfal ta’inqas minn eta`ta’ 4snin

with other antiepileptic medicines (add-on therapy) to treat:
biex jiżdied ma’ mediċini oħra (terapija addizzjonali) ta’ kontra l-epilessija fit-trattament ta’:

add-on therapy for infants aged from 1 month to less than 6 months
terapija għat-trabi b'età minn xahar 1sa inqas minn 6 xhur

linagliptin as add-on therapy in elderly (age ≥ 70 years) with type 2 diabetes
linagliptin bħala terapija addizzjonali fl-anzjani (età ta’ ≥ 70 sena) b’dijabete ta’ tip 2

fycompa must only be used as an ‘add-on’ therapy to other anti-epileptic medicines.
fycompa għandu jintuża biss bħala żieda ma’ mediċini antiepilettiċi oħrajn.

patients enrolled into the epoprostenol add-on therapy study were eligible to enter a long term open label extension study.
pazjenti mdaħħla fl-istudju fejn epoprostenol huwa miżjud mat-terapija kienu eliġibbli li jidħlu fi studju estiż b’tikketta miftuħa fuq tul ta’ żmien twil.

add-on therapy for children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg
terapija aġġuntiva fi tfal bejn l-4 snin sa 11-il sena u adolexxenti (12 sa 17-il sena) li jiżnu inqas minn 50 kg

add-on therapy for adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more
terapija aġġuntiva għal adulti (≥18 sena ) u adolexxenti (12 sa 17-il sena) li jiżnu 50 kg jew iżjed.

14 tablets 30 tablets 42 tablets 56 tablets 90 tablets 100 tablets starter pack 42 tablets, non-valproate add-on therapy
14 – il pillola 30 pilloli 42 pilloli 56 pilloli 90 pilloli 100pilloli pakkett tal- bidu 42 pilloli valproate terapija add- on

the use of prostacyclin, prostacyclin analogues and endothelin receptor antagonists was not permitted as add-on therapy, and neither was arginine supplementation.
l-użu ta’ prostacyclin, prostacyclin analogues u endothelin receptor antagonists ma kienx permess bħala terapija miżjuda, u lanqas suppliment ta’ arginine.

ranexa demonstrated greater efficacy than placebo in prolonging exercise time at trough at 12 weeks for both doses studied when used as an add-on therapy.
ranexa wriet effikaċja akbar minn plaċebo fit-titwil taż-żmien ta’ eżerċizzju f’livelli minimi, f’ġimgħa 12 għaż-żewġ dożi studjati meta wżata bħala terapija add-on.

the incidence of reported hypoglycaemia for saxagliptin 5 mg versus placebo given as add-on therapy to metformin was 5.8% versus 5%.
il-frekwenza ta’ glucose baxx fid-demm għal saxagliptin 5 mg kontra l-plaċebo mogħti bħala terapija miżjuda ma’ metformin kienet 5.8% kontra 5%.